Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer
Wentao Tian,Chenghui Cao,Long Shu,Fang Wu
DOI: https://doi.org/10.2147/OTT.S276150
IF: 4
2020-11-24
OncoTargets and Therapy
Abstract:Wentao Tian, 1, 2 Chenghui Cao, 1, 2 Long Shu, 1 Fang Wu 1 1 Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, People's Republic of China; 2 Xiangya School of Medicine, Central South University, Changsha 410013, Hunan, People's Republic of China Correspondence: Fang Wu Department of Oncology, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, People's Republic of China Tel +86 13574858332 Email wufang4461@csu.edu.cn Angiogenesis plays an essential role in the development of most solid tumors by delivering nutrients and oxygen to the tumor. Therefore, anti-angiogenic therapy, particularly anti-VEGF and anti-VEGF receptor (VEGFR) therapy, has been a popular strategy to treat cancer. However, anti-angiogenic therapy does not significantly improve patients' outcomes when used alone because the cutdown of the vessels transforms tumor cells to a hypoxia-tolerant phenotype. While combining anti-angiogenic therapy with other therapies, including chemotherapy, radiotherapy, immunotherapy, and anti-epidermal growth factor receptor (EGFR) therapy, has a promising efficacy due to the vessel normalization effect induced by anti-angiogenic agents. Here, we review the characteristics of tumor angiogenesis, the mechanisms, clinical applications, and prospects of combining anti-angiogenic therapy with other therapies in the treatment of non-small cell lung cancer. Keywords: angiogenesis, non-small cell lung cancer, anti-angiogenesis therapy, combination therapy, immunotherapy
oncology,biotechnology & applied microbiology